SYN120 Study to Evaluate Its Safety, Tolerability and Efficacy in Parkinson's Disease Dementia (SYNAPSE)
Status:
Completed
Trial end date:
2017-10-03
Target enrollment:
Participant gender:
Summary
The purpose of this study placebo-controlled, randomized, double-blind study is to assess the
safety and efficacy of SYN120 in patients with Parkinson's disease dementia (PDD) already
treated with a stable dose of a cholinesterase inhibitor.
Phase:
Phase 2
Details
Lead Sponsor:
Biotie Therapies Inc.
Collaborators:
Acorda Therapeutics Massachusetts General Hospital Michael J. Fox Foundation for Parkinson's Research Parkinson's Study Group